This article is more than 5 years old. Information may no longer be current.
Top hematology/oncology stories: Trial to assess CAR T-cell therapy, FDA approves Copiktra
Among the top stories in hematology/oncology this week were the announcement of a trial to assess CAR T-cell therapy for relapsed and refractory solid tumors for children and young adults and the FDA approval of Copiktra for leukemia and lymphoma subtypes.
Other top stories included findings that pembrolizumab for melanoma may cause antiphospholipid syndrome, a novel gene expression tool predicts immunotherapy response among patients with melanoma and opioid deaths are significantly less common among individuals with cancer.
Trial to assess CAR T-cell therapy for relapsed, refractory solid tumors
A trial underway at Seattle Children’s Hospital will evaluate chimeric antigen receptor T-cell therapy for children and young adults with relapsed or refractory noncentral nervous system EGFR-expressing solid tumors. Read more.
FDA approves Copiktra for leukemia, lymphoma subtypes
The FDA approved duvelisib for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two prior therapies. Read more.
Pembrolizumab for melanoma may cause antiphospholipid syndrome
Antiphospholipid syndrome occurred following treatment with pembrolizumab for unresectable, stage IIIB melanoma, according to a research letter. Read more.
Tool predicts immunotherapy response among patients with melanoma
A novel gene expression predictor effectively predicted whether patients with melanoma would respond to immune checkpoint inhibitors, according to study results published in Nature Medicine. Read more.
Opioid deaths significantly less common among individuals with cancer
Individuals with cancer appeared 10 times less likely than the general population to die as a result of opioid use, according to retrospective study results presented at ASCO Quality Care Symposium. Read more.